Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions

• Published in: Annals of the rheumatic diseases 2000-07, Vol.59 (7), p.544-548
• Main Authors: Vos, K, Steenbakkers, P, Miltenburg, A M M, Bos, E, van den Heuvel, M W, van Hogezand, R A, de Vries, R R P, Breedveld, F C, Boots, A M H
• Format: Article
• Language: English
• Subjects: Adipokines; Adult; Aged; Analysis of Variance; Arthritis, Rheumatoid - blood; Arthritis, Rheumatoid - pathology; biochemical markers; Biological and medical sciences; Chitinase; Chitinase-3-Like Protein 1; Crohn's disease; Enzyme-Linked Immunosorbent Assay; Extended Report; Female; Glycoproteins; Glycoproteins - blood; Health risk assessment; human cartilage glycoprotein-39; Humans; Hypotheses; Inflammatory bowel disease; Inflammatory Bowel Diseases - blood; Investigative techniques, diagnostic techniques (general aspects); Lectins; Lupus Erythematosus, Systemic - blood; Lymphocytes; Male; Measurement; Medical sciences; Middle Aged; Molecular weight; Neutrophils; Osteoarthritis - blood; Osteoarticular system. Muscles; Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques; Physiological aspects; Plasma; Proteins; Rheumatoid arthritis; Rheumatology; Studies; YKL-40
• ISSN: 0003-4967; 1468-2060
• DOI: 10.1136/ard.59.7.544

OBJECTIVE To evaluate plasma human cartilage glycoprotein (HC gp-39) as a possible marker for the presence and/or activity of rheumatoid arthritis (RA) and other inflammatory conditions. BACKGROUND HC gp-39 is a secretory product of chondrocytes, synovial cells, macrophages, and neutrophils. HC gp-39, also described as YKL-40, was found to be a marker of joint disease and tissue injury in RA and various other diseases. METHODS Levels of HC gp-39 were determined by a sandwich enzyme linked immunosorbent assay (ELISA) in 47 patients with RA, 47 with osteoarthritis (OA), 24 with systemic lupus erythematosus (SLE), 24 with inflammatory bowel disease (IBD), and in 47 healthy controls. A disease activity score was assessed in the patients with RA, SLE, and IBD. RESULTS The plasma level of HC gp-39 in the RA patient group was significantly higher than in the other patient groups and healthy controls. The level in patients with OA, SLE, and IBD was also significantly higher than the HC gp-39 level found in the healthy control group. HC gp-39 levels in patients with RA correlated positively with the ESR and IgM rheumatoid factor level but not with other variables of disease activity. In the patients with SLE and IBD no correlation was found with the disease activity score. CONCLUSION The plasma level of HC gp-39 is increased in inflammatory conditions with and without joint disease (SLE, IBD, OA, and RA). Thus increased levels of HC gp-39 do not only reflect joint disease but also reflect inflammation or tissue degradation in various conditions. Notably, the highest level of HC gp-39 was found in patients with RA. Only in the RA patient group was a correlation between HC gp-39 plasma levels and some laboratory variables of disease activity found.